Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Accounts Payables (2016 - 2025)

Rein Therapeutics has reported Accounts Payables over the past 10 years, most recently at $4.0 million for Q4 2025.

  • Quarterly Accounts Payables rose 336.44% to $4.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Dec 2025, up 336.44% year-over-year, with the annual reading at $4.0 million for FY2025, 336.44% up from the prior year.
  • Accounts Payables was $4.0 million for Q4 2025 at Rein Therapeutics, down from $4.1 million in the prior quarter.
  • Over five years, Accounts Payables peaked at $6.0 million in Q2 2025 and troughed at $136000.0 in Q2 2023.
  • The 5-year median for Accounts Payables is $1.1 million (2021), against an average of $1.6 million.
  • Year-over-year, Accounts Payables crashed 92.19% in 2023 and then soared 670.84% in 2025.
  • A 5-year view of Accounts Payables shows it stood at $1.2 million in 2021, then soared by 42.15% to $1.7 million in 2022, then crashed by 30.81% to $1.2 million in 2023, then fell by 23.45% to $911000.0 in 2024, then soared by 336.44% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for RNTX's Accounts Payables are $4.0 million (Q4 2025), $4.1 million (Q3 2025), and $6.0 million (Q2 2025).